Chutes & Ladders—AIRNA appoints Elevidys architect as CMO
Just a few weeks after closing a $155 million series B, RNA editing biotech AIRNA is bringing an experienced gene therapy developer on board to help get the company’s first candidate into the clinic.
Just a few weeks after closing a $155 million series B, RNA editing biotech AIRNA is bringing an experienced gene therapy developer on board to help get the company’s first candidate into the clinic.
